Patient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma
Open Access
- 17 February 2021
- Vol. 10 (2), 416
- https://doi.org/10.3390/cells10020416
Abstract
Osteosarcoma (OS) is a rare malignant primary tumor of mesenchymal origin affecting bone. It is characterized by a complex genotype, mainly due to the high frequency of chromothripsis, which leads to multiple somatic copy number alterations and structural rearrangements. Any effort to design genome-driven therapies must therefore consider such high inter- and intra-tumor heterogeneity. Therefore, many laboratories and international networks are developing and sharing OS patient-derived xenografts (OS PDX) to broaden the availability of models that reproduce OS complex clinical heterogeneity. OS PDXs, and new cell lines derived from PDXs, faithfully preserve tumor heterogeneity, genetic, and epigenetic features and are thus valuable tools for predicting drug responses. Here, we review recent achievements concerning OS PDXs, summarizing the methods used to obtain ectopic and orthotopic xenografts and to fully characterize these models. The availability of OS PDXs across the many international PDX platforms and their possible use in PDX clinical trials are also described. We recommend the coupling of next-generation sequencing (NGS) data analysis with functional studies in OS PDXs, as well as the setup of OS PDX clinical trials and co-clinical trials, to enhance the predictive power of experimental evidence and to accelerate the clinical translation of effective genome-guided therapies for this aggressive disease.Keywords
Funding Information
- Ministero della Salute (RF-2016-02361373)
This publication has 104 references indexed in Scilit:
- Wee1 Inhibition by MK-1775 Leads to Tumor Inhibition and Enhances Efficacy of Gemcitabine in Human SarcomasPLOS ONE, 2013
- A Review of Targeted Therapies Evaluated by the Pediatric Preclinical Testing Program for OsteosarcomaFrontiers in Oncology, 2013
- Integrative Analysis Reveals Relationships of Genetic and Epigenetic Alterations in OsteosarcomaPLOS ONE, 2012
- Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissueJournal of Translational Medicine, 2012
- Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistanceProceedings of the National Academy of Sciences of the United States of America, 2011
- Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer DevelopmentCell, 2011
- International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly personsInternational Journal of Cancer, 2009
- Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progressionBMC Genomics, 2009
- Phenotypic instability of Saos-2 cells in long-term cultureBiochemical and Biophysical Research Communications, 2005
- Survival of children with bone sarcoma in Europe since 1978: results from the EUROCARE studyEuropean Journal of Cancer, 2001